AstraZeneca PLCAZN
Closing prices as of Sep 15, 2026Updated once daily after the US close — not a live quote.

$162.00

+3.20% past month

Notable price movement

  • Sep 15, 2026

    $161.85-1.18%

  • Sep 14, 2026

    $163.78+2.25%

    The stock rose 2.25% on the day, a move not shared by the broader market, which saw the S&P 500 ETF (SPY) fall 0.45% during the same session .

  • Sep 11, 2026

    $160.17+0.33%

  • Sep 10, 2026

    $159.64+1.72%

  • Sep 9, 2026

    $156.94-1.94%

  • Sep 8, 2026

    $160.04-1.63%

    A drug combination from Amgen and AstraZeneca extended survival in a late-stage lung cancer trial . Trading volume was 1.6 times the trailing average and the shares moved across a 2.9% range during the session .

  • Sep 4, 2026

    $162.70-1.26%

    AstraZeneca shares slipped 1.26% on a day when the FDA granted accelerated approval to the company's camizestrant (Etcamah) for HR+, HER2- breast cancer .

Closing prices for AZN. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Recent news

The Motley Fool1 day agoAlnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter PictureSeeking Alpha4 days agoAstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open LongYahoo FinanceAug 15, 2026Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?Pr NewswireAug 7, 2026INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZNThe Motley FoolSep 3, 2026Here's Why Ionis Pharmaceuticals' Steep Sell-off Was OverdoneSeeking Alpha4 days agoAstraZeneca's Etcamah fails in late-stage trial as first-line breast cancer treatment

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.

Prices and financial data are historical and provided for research only. Not investment advice.